Tagrix – A Project of Reinforcelab
Tagrix (Osimertinib) is a product website which is a blockbuster product of Beacon Pharmaceuticals Limited. the first of its kind to be indicated for patients with T790M mutation-positive NSCLC, irrespective of previous treatment with an EGFR tyrosine kinase inhibitor (TKI). Tagrix (Osimertinib) targets both the EGFR mutation that triggers cancer development and T790M. Tagrix is the first global generic preparation of Tagrix (Osimertinib) which is approved by Directorate of Drug Administration, Ministry of Health and Family Welfare, People’s Republic of Bangladesh.
We have ensured best quality design for the Tagrix website to make it user friendly for the customers . We have also set call action to increase the sales rate of the product. We also tried to make the full quality product’s website with an affordable price.